Cover Image
市場調查報告書

B細胞非何杰金氏淋巴瘤:開發中產品分析

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251598
出版日期 內容資訊 英文 1101 Pages
訂單完成後即時交付
價格
Back to Top
B細胞非何杰金氏淋巴瘤:開發中產品分析 B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016
出版日期: 2016年10月29日 內容資訊: 英文 1101 Pages
簡介

非何杰金氏淋巴瘤(NHL),是從身體的免疫系的一部分,被稱作為淋巴球的細胞發病的癌症。淋巴球的2大類型,是B淋巴球(B細胞)和T淋巴球(T細胞)。BB淋巴球(B細胞)來源的癌症,是B細胞非何杰金氏淋巴瘤。一般的徵兆與症狀為淋巴節的腫大(疼痛)、發熱、盜汗、原因不明的體重減少、活力不足等。治療有外科手術、放射線治療、化療等。

本報告提供B細胞非何杰金氏淋巴瘤的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

  • 簡介
  • B-Cell Non-Hodgkin Lymphoma概要
  • 治療藥的開發
  • B-Cell Non-Hodgkin Lymphoma:企業開發中的治療藥
  • B-Cell Non-Hodgkin Lymphoma:大學/機關研究中的治療藥
  • B-Cell Non-Hodgkin Lymphoma:開發中產品概況
  • B-Cell Non-Hodgkin Lymphoma:企業開發中的產品
  • B-Cell Non-Hodgkin Lymphoma:大學/機關研究中的產品
  • B-Cell Non-Hodgkin Lymphoma的治療藥的開發企業
  • B-Cell Non-Hodgkin Lymphoma:治療藥的評估
  • 藥物簡介
  • B-Cell Non-Hodgkin Lymphoma:最近的開發平台趨勢
  • B-Cell Non-Hodgkin Lymphoma:暫停中的計劃
  • B-Cell Non-Hodgkin Lymphoma:開發中止的產品
  • B-Cell Non-Hodgkin Lymphoma:產品開發的里程碑
  • 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8609IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016, provides an overview of the B-Cell Non-Hodgkin Lymphoma (Oncology) pipeline landscape.

Non-Hodgkin lymphoma (also known as non-Hodgkin's lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body's immune system. The two main types of lymphocytes are B lymphocytes (B cells) and T lymphocytes (T cells). Cancer that starts from B lymphocytes (B cells) is known as B Cell Non-Hodgkin Lymphoma. Common signs and symptoms of B Cell Non-Hodgkin Lymphoma include swelling of the lymph nodes (which is often but not always painless), fever, night sweats, unexplained weight loss and lack of energy. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for B-Cell Non-Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The B-Cell Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for B-Cell Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 2, 17, 90, 57, 2, 68, 9 and 1 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 4, 8 and 2 molecules, respectively for B-Cell Non-Hodgkin Lymphoma.

B-Cell Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for B-Cell Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in B-Cell Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates B-Cell Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for B-Cell Non-Hodgkin Lymphoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for B-Cell Non-Hodgkin Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding B-Cell Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • B-Cell Non-Hodgkin Lymphoma Overview
  • Therapeutics Development
  • B-Cell Non-Hodgkin Lymphoma - Therapeutics under Development by Companies
  • B-Cell Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes
  • B-Cell Non-Hodgkin Lymphoma - Pipeline Products Glance
  • B-Cell Non-Hodgkin Lymphoma - Products under Development by Companies
  • B-Cell Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes
  • B-Cell Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development
  • B-Cell Non-Hodgkin Lymphoma - Therapeutics Assessment
  • Drug Profiles
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects
  • B-Cell Non-Hodgkin Lymphoma - Discontinued Products
  • B-Cell Non-Hodgkin Lymphoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H2 2016
  • Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Development by Companies, H2 2016 (Contd..17)
  • Products under Development by Companies, H2 2016 (Contd..18)
  • Products under Development by Companies, H2 2016 (Contd..19)
  • Products under Development by Companies, H2 2016 (Contd..20)
  • Products under Development by Companies, H2 2016 (Contd..21)
  • Products under Development by Companies, H2 2016 (Contd..22)
  • Products under Development by Companies, H2 2016 (Contd..23)
  • Products under Development by Companies, H2 2016 (Contd..24)
  • Products under Development by Companies, H2 2016 (Contd..25)
  • Products under Development by Companies, H2 2016 (Contd..26)
  • Products under Development by Companies, H2 2016 (Contd..27)
  • Products under Development by Companies, H2 2016 (Contd..28)
  • Products under Development by Companies, H2 2016 (Contd..29)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH , H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corporation, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Ariad Pharmaceuticals, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Arvinas, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Asana BioSciences, LLC, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Limited, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by BeiGene, Ltd., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Bio-Path Holdings, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Biocon Limited, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Biogen Inc, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Biogenomics Limited, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by BioNTech AG, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Biothera Pharmaceutical Inc, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by bluebird bio, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Cell Medica Limited, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Cell>Point, L.L.C., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Celltrion, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Clevexel Pharma SA, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by CrystalGenomics, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by CTI BioPharma Corp., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Curis, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by eFFECTOR Therapeutics, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Eisai Co., Ltd., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by EpiZyme, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Erytech Pharma SA, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Evotec AG, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Genentech, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Genor BioPharma Co Ltd, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Genosco, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by H3 Biomedicine Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Hutchison MediPharma Limited, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by IGF Oncology, LLC., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by ImmunoGen, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Immunovaccine, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Incyte Corporation, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Inflection Biosciences Limited, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by JHL Biotech, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Kite Pharma Inc, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by LFB S.A., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by mAbxience S.A., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by MacroGenics, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by MedImmune, LLC, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Medivation, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by MEI Pharma, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Molplex Ltd., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Nimbus Therapeutics, LLC, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by NovImmune SA, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Onconova Therapeutics, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Oncternal Therapeutics, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by OXIS International, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Patrys Limited, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by RedHill Biopharma Ltd., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Respiratorius AB, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Sandoz International GmbH, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Sanofi, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Selvita S.A., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Simcere Pharmaceutical Group, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Sutro Biopharma, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Takara Bio Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Transgene SA, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by United BioPharma, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics, Inc., H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Vivolux AB, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences (UK) Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..1), H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..2), H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..3), H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..4), H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..5), H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..6), H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..7), H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..8), H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..9), H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..10), H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..11), H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..12), H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..13), H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Discontinued Products, H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..1), H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..2), H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..3), H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..4), H2 2016
  • B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..5), H2 2016

List of Figures

  • Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H2 2016
  • Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top